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ABSTRACT (250 word max) 
Background: Peripheral (plasma) and central (cerebrospinal fluid, CSF) measures of tau are increased in 
Alzheimer’s disease (AD) relative to prodromal stages and controls. While elevated CSF tau levels have 
been shown to be associated with lower grey matter density (GMD) in AD-specific regions, this 
correlation has yet to be examined for plasma in a large study. 
Methods: Cross-sectional data for 508 ADNI participants were collected for clinical, plasma tau, CSF 
amyloid (Aβ42) and tau, and MRI variables. The relationship between plasma tau and GMD and between 
CSF total-tau (t-tau) and GMD were assessed on a voxel-by-voxel basis using regression models. Age, 
gender, APOE ε4 status, diagnosis, and intracranial volume were used as covariates where appropriate. 
Participants were defined as amyloid positive (Aβ+) if CSF Aβ42 was <192pg/mL. 
Results: Plasma tau was negatively correlated with GMD in the medial temporal lobe (MTL), precuneus, 
thalamus, and striatum. The associations with thalamus and striatum were independent of diagnosis. A 
negative correlation also existed between plasma tau and GMD in Aβ+ participants in the MTL, 
precuneus, and frontal lobe. When compared to CSF t-tau, plasma tau showed a notably different 
associated brain atrophy pattern, with only small overlapping regions in the fusiform gyrus. 
Conclusions: Increased plasma tau was associated with atrophy in several AD-specific brain regions, as 
well as in the striatum and thalamus. These findings support plasma tau as a peripheral marker of 
ongoing AD-type neurodegeneration. The reduced GMD in thalamic and striatal regions associated with 
plasma tau suggest that this association may not be AD-specific. 
 
KEYWORDS (4-10): plasma; tau protein; magnetic resonance imaging; mild cognitive impairment; 
Alzheimer disease 
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INTRODUCTION 
 Understanding the underlying pathological processes of Alzheimer’s disease (AD) and 
developing reliable biomarkers are critical to identify the causes and pathogenesis of AD. Both in vivo 
and post-mortem studies have shown that pathological tau is correlated with neurodegeneration, 
disease severity, and cognitive impairment [1]. Likewise, in vivo central measures of tau in cerebrospinal 
fluid (CSF) also correlate with post-mortem tau pathology and are increased in AD patients relative to 
those in a prodromal stage of AD referred to as mild cognitive impairment (MCI) and cognitively normal 
controls (CN), aiding prediction of disease progression [2, 3]. However, CSF collection is regarded as 
invasive, leading researchers to search for alternative methods to monitor MCI and AD such as blood 
biomarkers.  
A recent meta-analysis reported plasma tau as the only blood-based biomarker to delineate AD 
from controls [4]. Fortunately, a new ultrasensitive technique was developed capable of detecting tau at 
low concentrations in plasma [REF= Randall ]. Similar to CSF, plasma tau levels are higher in AD relative 
to MCI and CN [5]. However, a large overlap was observed between the MCI and CN groups suggesting 
plasma tau may not be suitable as a diagnostic marker. Further, the correlation between plasma tau and 
CSF tau was weak [5].  
Previous studies have reported conflicting results regarding CSF tau and its correlation with 
cortical atrophy [6]. The goal of our project was to investigate the association of plasma tau with 
atrophy in participants of the ADNI. We also aimed to determine if plasma  and CSF tau levels were 
related to atrophy in similar brain regions. We hypothesize that plasma tau will be inversely correlated 
with grey matter density (GMD), as is seen with a majority of studies with CSF tau. Secondly, we 
hypothesize that plasma tau and CSF t-tau will be related to similar regions of atrophy.  
 
MATERIALS and METHODS 
 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
Subjects used in this study were participants in the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) (www.adni-info.org). The ADNI was launched in 2004 to help researchers and clinicians develop 
new treatments for MCI (mild cognitive impairment) and early AD, monitor their effectiveness, and 
decrease the time and cost of clinical trials.  The Principal Investigator of this initiative is Michael W. 
Weiner, M.D., VA Medical Center and University of California, San Francisco. The goal of ADNI is to test 
whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological 
markers, and clinical and neuropsychological assessment can be combined to measure the progression 
of MCI and AD.  This multi-year multi-site longitudinal study was started by the National Institute on 
Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug 
Administration (FDA), private pharmaceutical companies, and non-profit organizations as a $60 million, 
5-year public-private partnership. The ADNI participants consist of AD, MCI, and elderly healthy 
individuals. They were aged 55-90 years and recruited from 59 sites across the U.S. and Canada. Written 
informed consent was obtained from all participants and the study was conducted with prior 
Institutional Review Board approval.   
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Plasma Tau Collection and Quality Control 
Peripheral plasma tau levels were measured for 581 non-Hispanic Caucasian participants using 
the Single Molecule array (Simoa) technique with the Human Total Tau assay (Human Total Tau 2.0 kit, 
Quanterix Corp, Boston, MA, USA). This assay and the plasma tau characteristics for ADNI have been 
previously described [5, 7]. In brief, the assay uses two monoclonal antibodies which bind to the N-
terminus and mid-region of tau, and measures both normal and phosphorylated tau protein. Values are 
given as pg/mL. A total of 38 samples had plasma levels below the Limit of Detection (LOD) or below the 
Lower Limit of Quantification (LLOQ) and were removed from further analysis. An additional four 
samples had missing values. To reduce the possible effect of extreme outliers on statistical analysis, the 
mean and standard deviation (SD) of plasma tau were calculated; participants with a value more than 
three SDs above or below the mean value were regarded as outliers and removed from further analysis. 
This resulted in the removal of eight participants, leaving 508 participants for the study (166 CN, 174 
MCI, 168 AD). 
 
CSF Collection and Quality Control 
CSF samples were available for 370 of the 508 ADNI plasma tau subjects with comparable 
demographic, clinical, and apolipoprotein (APOE) genotyping results to the full sample [8]. Briefly, a 
lumbar puncture was performed after an overnight fast and the CSF was collected into collection tubes. 
The CSF was transferred into polypropylene tubes, frozen on dry ice within one hour of collection, and 
then shipped to the ADNI Biomarker Core laboratory at the University of Pennsylvania Medical Center 
on dry ice. Aliquots (0.5ml) were prepared from these samples after one hour of thawing at room 
temperature and stored in bar code-labeled polypropylene vials at -80°C.  
CSF analytes (Aβ1-42, t-tau and p-tau181p) were measured using the multiplex xMAP Luminex 
platform (Luminex Corp, Austin, TX) with Innogenetics (INNO-BIA AlzBio3; Ghent, Belgium; for research 
use-only reagents) immunoassay kit-based reagents. To reduce the possible effect of outliers on 
statistical analysis, the mean and standard deviation of CSF analytes were calculated and subjects with 
at least one analyte value more than three SD below or above the mean value of each of CSF variable 
were regarded outliers and removed from the analysis.  This resulted in 341 valid CSF samples.  For the 
MRI-CSF study, only participants with a CSF value for both t-tau and p-tau were included in the CSF study 
(91 CN, 158 MCI, 82 AD). Participants were classifies as amyloid positive (Aβ+) if CSF Aβ1-42 <192pg/mL. 
 
MRI Scan Processing 
All participants had baseline 1.5T magnetization-prepared rapid gradient-echo (MPRAGE) 
images downloaded from the ADNI LONI site (http://adni.loni.usc.edu/). Scan processing with voxel-
based morphometry (VBM) in Statistical Parametric Mapping 8 (SPM8; Wellcome Trust Centre for 
Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) and quality control were done as 
previously described [9]. Briefly, scans were co-registered to a T1-weighted template and segmented 
into different tissue classes (gray matter, GM; white matter, WM; CSF). Grey matter maps were 
normalized to MNI space without modulation as 1 x 1 x 1 mm voxels and smoothed with an 8 mm 
Gaussian kernel to create GM density (GMD) images for further analysis.  
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Image Analysis 
 To evaluate the relationship between central (CSF) and peripheral (plasma) measures of tau and 
GMD, voxel-wise linear regression models in SPM8 were used. Covariates included in the regression 
models were age, gender, APOE status (ε4 carrier or ε4 non-carrier), and total intracranial volume, 
generated using Freesurfer version 5.1. Analyses were done with and without diagnosis. An explicit GM 
mask was applied to the MRI scans to restrict the search area for the statistical analysis. Significant 
results were displayed at a voxel-wise p < 0.05 (family-wise error (FWE) corrected for multiple 
comparisons) and with a minimum cluster size (k) of 100 voxels. If no brain regions survived correction 
for multiple comparisons, then a slightly less stringent voxel-wise p-value of 0.001 (uncorrected) was 
used. To determine if there were any overlapping brain regions significantly correlated to plasma tau 
and CSF, a composite image was created in SPM8. 
 
Statistical Analysis 
SPSS V24.0 was used to log transform the CSF t-tau and p-tau values in order to achieve normal 
distribution. Plasma tau values were normally distributed and thus absolute values were used for 
analysis; results were unchanged when a transformed plasma value was use. The association of gender, 
APOE status, and Aβ positivity with diagnostic groups was assessed using a Pearson chi-squared test. 
ANOVA was used to assess the relationship of age, Mini-Mental State Exam (MMSE), Clinical Dementia 
Rating Scale – Sum of Boxes (CDR-SB), plasma tau, and CSF analytes with diagnostic status. Post-hoc 
pairwise differences among diagnostic groups was assessed using a Bonferroni correction for multiple 
comparisons. The MarsBaR toolbox in SPM8 was used to extract mean GMD from significant clusters 
from the voxel-wise results for further characterization of the results.   
 
Results 
 
Demographic and clinical characteristics 
There was a near equal number of subjects in each diagnostic group with 166 CN, 174 MCI, and 
168 AD. Significant differences among diagnostic groups were observed for all demographic and clinical 
characteristics examined except for age (Table 1). As expected, the AD group had the highest percentage 
of APOE ε4 carriers (67.9%), followed by the MCI group consisting of 54% APOE ε4 carriers. Significant 
differences in the mean MMSE and CDR-SB among the diagnostic groups, with the AD group showing 
the most impairment and the MCI group showing intermediate impairment between AD and CN (p < 
0.001). Plasma tau, CSF t-tau, and CSF p-tau were significantly different between groups, with the AD 
group showing significantly higher levels compared to MCI and CN (p = 0.002, p < 0.001, and p < 0.001, 
respectively). Similar to previous reports, the mean plasma tau levels in the MCI and CN groups were 
nearly equal. The number of Aβ+ subjects was also significantly different among diagnostic groups (p < 
0.001). 
 
Voxel-based MRI analysis 
A significant negative association between increased plasma tau and decreased GMD in several 
brain regions was observed, including in the middle, inferior, and superior temporal gyrus, 
parahippocampus, hippocampus, fusiform, uncus, precuneus, thalamus, caudate, putamen, and middle 
and inferior frontal gyrus (Fig. 1A-D, voxel-wise p<0.001 (uncorrected), k=100 voxels). As would be 
expected, AD participants had lower mean GMD in the larger clusters identified (MTL structures, 
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striatum, and thalamus; Supplemental Fig.1A). When controlling for diagnosis, a significant negative 
association between plasma tau and GMD was still observed in the right thalamus and bilaterally in the 
striatum (Fig. 1C-D). No significant clusters were observed in the positive direction (data not shown). 
 
Amyloid-positive subjects 
 There was no significant association between plasma tau and GMD in the Aβ- subjects, however 
increased plasma tau was significantly correlated with decreased GMD in the Aβ+ subjects in the 
fusiform, hippocampus, parahippocampus, precuneus, and premotor cortex (Fig. 2A-D, voxel-wise 
p<0.001 (uncorrected), k=100 voxels), as well as the frontal and parietal lobes, pre- and post-central 
gyri, and the globus pallidus. Notably, in the MTL cluster, Aβ+ subjects showed lower mean GMD 
compared to Aβ- subjects (Supplemental Fig. 1B). After diagnosis was added as a covariate, many of the 
same regions of reduced GMD remained significantly negatively correlated with increased plasma tau 
including in the precuneus, parahippocampus, and premotor cortex (Fig. 2B-D). No significant clusters 
were observed in the positive/unexpected direction (data not shown).  
 
CSF-Plasma tau comparison 
Peripheral measures of tau protein were of total-tau only, thus, we sought to compare the 
regional atrophy associated with plasma tau to that associated with CSF t-tau only. At p < 0.05 (FWE 
corrected), increased CSF t-tau was negatively associated with reduced GMD in the precuneus and 
temporal gyrus (Supplemental Fig. 2). However, the uncorrected results were used for comparison with 
the plasma tau results, as this threshold was used in the plasma tau analyses described above. Central 
and peripheral measures of tau protein were associated with GMD in some overlapping, but largely 
different brain regions. The temporal pole, fusiform, and angular gyrus were brain regions in which both 
increased CSF t-tau and plasma tau were associated with reduced GMD (Fig. 3A-D). As several reports 
have previously shown, increased CSF t-tau was associated with lower GMD in cortical structures known 
to be affected in persons with AD. However, as above, in the present study plasma tau was 
predominantly associated with subcortical structures. Within the Aβ+ subjects, no significant overlap 
was observed between the association of GMD with plasma tau and the association of GMD with CSF t-
tau (data not shown).  
 
Discussion 
 The main goal of this study was to determine if plasma tau was associated with cortical atrophy 
in a population at risk for AD or already manifesting signs of clinical  AD. We found increased plasma tau 
was negatively correlated with reduced GMD in several AD-specific brain regions, including the MTL and 
precuneus, as well as in the thalamus and striatum. Further investigation into only Aβ+ subjects also 
revealed an association between increased plasma tau levels and reduced GMD in MTL structures, the 
precuneus, and the premotor cortex. When the pattern of GM atrophy associated with increased plasma 
tau was compared to that associated with increased CSF t-tau, only small regions of overlap were 
observed in the temporal pole, fusiform, and angular gyrus. Otherwise, the central (i.e. CSF) and 
peripheral (i.e. plasma  levels of tau showed quite different associated patterns of atrophy. These 
findings suggest that plasma tau may reflect neurodegeneration in AD-specific regions and more 
generally.  
 The MTL is one of the first brain regions that shows  tau pathology and the earliest to 
degenerate in AD patients [10]. Thus, our observation that high plasma tau is associated with cortical 
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atrophy in several MTL structures including the parahippocampus and hippocampus across all subjects 
and in Aβ+ subjects suggests that this peripheral measure of tau may be reflective of CSF  and brain tau 
pathology as well as brain atrophy. We also observed a negative correlation between increased plasma 
tau and reduced GMD in the precuneus. A functional decline in the precuneus occurs early in the  course 
of AD, but tau deposition normally occurs in later stages. Specifically, the precuneus along with the 
hippocampus are both core components of the default mode network, an important functional resting-
state network that is impaired early in AD [11]. Thus, the atrophy in the precuneus associated with 
plasma tau could be reflective of structural deterioration in the default mode network early in AD.  
Even more striking was the inverse association of plasma tau with GMD in the thalamus and the 
striatum across all subjects, especially given that these areas are affected later in the disease course. 
These were the only brain regions that were also independent of diagnosis, suggesting that plasma tau 
may reflect neurodegeneration unrelated to AD diagnosis. Alternatively, in the Aβ+ subjects, the 
association of plasma tau and GMD in the parahippocampus and precuneus was independent of 
diagnosis. These findings suggest that plasma tau may be reflecting neurodegeneration specific to AD 
pathology. Taken together, the results independent of diagnosis suggests that plasma tau may be 
reflecting disease-specific neurodegeneration in different regions, with associated atrophy in AD-
relevant regions linked to AD pathology and associated atrophy in other regions potentially reflecting 
other pathology or a more general neurodegeneration. Studies evaluating plasma tau in other 
tauopathies may shed light on this hypothesis. 
Our initial hypothesis was that plasma tau and CSF t-tau would be related to similar regions of 
atrophy, especially if the two tau measures were truly reflective of AD neurodegeneration. 
Unexpectedly, plasma tau and CSF t-tau had very little overlap, with plasma tau mapping more to 
subcortical structures and CSF t-tau mapping more to cortical structures. Only small regions of overlap 
were observed in the temporal pole, fusiform, and angular gyrus. These results suggest that CSF and 
plasma measures of tau protein may reflect related but somewhat different pathological substrates of 
AD. This could be due to differences in the assays, tau isoforms detected by the assays, or in the 
variability of the measurements. There may also be differences in how tau, released from neurons, is 
cleared from brain interstitial fluid to CSF and plasma. Further work is needed to further elucidate the 
differences between plasma and CSF tau. 
One study limitation is the lack of a commensurate replicate data set. This tau quantification 
method is relatively new and hopefully independent data sets will become available. Additionally, 
accumulated p-tau is the main hallmark in AD and other tauopathies but there is not yet a technique for 
measuring p-tau in plasma, thus yielding a second limitation to this study. New techniques to assess p-
tau in plasma could be extremely beneficial. A third limitation is that our data is cross-sectional only. 
Longitudinal data would provide us the information needed to better assess changes in plasma tau over 
time and the association between changing plasma tau measures and rate of neurodegeneration. 
 In conclusion, high levels of plasma tau were associated with lower grey matter density in both 
AD-specific and non-AD-related brain regions. Future replication and longitudinal studies will be 
important to fully elucidate the contribution of plasma tau as a possible biomarker in AD and other 
tauopathies.  
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Table 1. Demographic and clinical characteristics.  
 
 CN MCI AD p-value 
N 166 174 168 - 
Age (years) 75.2 (5.1) 74.1 (7.6) 75.3 (7.3) 0.789 
Gender (M, F) 95, 71 115, 59 87, 81 0.025 
APOE ε4 (% ε4 positive) 27.1% 54% 67.9% <0.001 
MMSE 29.1 (1) 26.9 (1.8) 23.2 (2) <0.001 
CDR-SB 0 (0.1) 1.6 (0.9) 4.3 (1.6) <0.001 
Plasma tau 2.7 (1) 2.8 (1.2) 3.1 (1.3) 0.002 
CSF t-tau* 65.7 (24.7) 97.6 (48.6) 121.2 (52.4) <0.001 
CSF p-tau* 22.3 (10.5) 34.3 (16.2) 41.5 (18.5) <0.001 
Amyloid (-/+)** 59, 32 41, 116 5, 76 <0.001 
CN = cognitively normal; MCI = mild cognitive impairment; AD = Alzheimer’s disease; M = male; F = 
female; APOE = apolipoprotein; MMSE = mini-mental state exam; CDR-SB = clinical dementia rating-sum 
of boxes; CSF = cerebrospinal fluid. Mean +/- standard deviation. Significant p-values < 0.05 are 
italicized. 
*n = 91 CN, 158 MCI, 82 AD 
**missing 1 MCI and 1 AD 
Figure 1: Increased plasma tau is negatively correlated with reduced grey matter density (GMD) in the 
(A) parahippocampus, (B) precuneus, (C) striatum, and (D) thalamus. C and D represent the anatomic 
overlap (orange) of regions of GM atrophy associated with increased plasma tau using only age, gender, 
APOE e4 status, and total intracranial volume as covariates (yellow) and with the addition of diagnosis as 
a covariate (red). Results are displayed at p<0.001 (uncorrected) and k=100 voxels in all figures.  
Figure 2: Increased plasma tau is negatively correlated with reduced GMD in the amyloid positive 
subjects in the (A) hippocampus, (B) precuneus, (C) parahippocampus, and (D) BA 6 premotor cortex. B-
D also represent the anatomic overlap (orange) of regions of GM atrophy associated with increased 
plasma tau using only age, gender, APOE e4 status, and total intracranial volume as covariates (yellow) 
and with the addition of diagnosis as a covariate (red). Results are displayed at p<0.001 (uncorrected) 
and k=100 voxels in all figures.  
Figure 3: Anatomical overlap of GM atrophy (orange) associated with increased plasma tau (red) and 
that associated with increased CSF t-tau (yellow). Results are displayed at p<0.001 (uncorrected) and 
k=100 voxels in all figures.  
Supplemental Figure 1: Mean GMD in selected regions significant in the voxel-wise analysis across (A) 
diagnostic and (B) amyloid status. Covariates included in both models include age, gender, APOE e4 
status, and total intracranial volume. 
Supplemental Figure 2: Increased CSF total-tau is negatively correlated with reduced GMD in the (A-B) 
precuneus, (C) fusiform, and (D) BA21. Covariates included in the analysis were age, gender, APOE e4 
status, and total intracranial volume. Results are displayed at p<0.05 (FWE corrected) and at a threshold 
(k) of 100 voxels. 
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